Obiltoxaximab

Obiltoxaximab, sold under the brand name Anthim, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[2][1][3]

Obiltoxaximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetBacillus anthracis anthrax
Clinical data
Trade namesAnthim
Other namesETI-204
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 1351337-07-9
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6444H9994N1734O2022S44
Molar mass145521.59 g·mol−1

This drug was developed by Elusys Therapeutics, Inc.[1][4]

Society and culture

In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment and prophylaxis of inhalational anthrax.[5]

On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for obiltoxaximab, intended for the treatment or post-exposure prophylaxis of inhalational anthrax.[6] The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH.[6] It was approved for medical use in the European Union in November 2020.[7]

References
  1. "Anthim- obiltoxaximab solution". DailyMed. 9 December 2019. Retrieved 21 September 2020.
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
  3. Hou AW, Morrill AM (October 2017). "Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection". The Annals of Pharmacotherapy. 51 (10): 908–913. doi:10.1177/1060028017713029. PMID 28573869. S2CID 39810240.
  4. "Anthim (obiltoxaximab) Injection". U.S. Food and Drug Administration (FDA). 26 April 2016. Retrieved 18 October 2020. Lay summary (PDF).
  5. Greig SL (May 2016). "Obiltoxaximab: First Global Approval". Drugs. 76 (7): 823–30. doi:10.1007/s40265-016-0577-0. PMID 27085536. S2CID 46099559.
  6. "Obiltoxaximab SFL: Pending EC decision". European Medicines Agency (EMA). 17 September 2020. Retrieved 21 September 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. "Obiltoxaximab EPAR". European Medicines Agency (EMA). 15 September 2020. Retrieved 27 November 2020.
  • "Obiltoxaximab". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.